<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573272</url>
  </required_header>
  <id_info>
    <org_study_id>FPS-ESL-2105-01</org_study_id>
    <nct_id>NCT02573272</nct_id>
  </id_info>
  <brief_title>Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors</brief_title>
  <official_title>Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on
      cardiovascular risk factors measured by biochemical and ultrasound parameters compared with
      enzyme-inducing AEDs.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Carotid IMT millimeters</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Epileptic patients with AEDs and eslicarbacepine</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eslicarbacepine</intervention_name>
    <arm_group_label>Epileptic patients with AEDs and eslicarbacepine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with focal epilepsy on stable treatment for the last two years
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years

          -  patients definitively diagnosed Focal Epilepsy based on clinical criteria and
             additional tests.

          -  patients with stable and identifiable antiepileptic treatment during the last two
             years.

          -  patients according to the investigator are able to provide clinical data necessary for
             the development of the study

          -  Patients who signed informed consent

        Exclusion Criteria:

          -  Patients who, according to their evolution and demands of clinical practice, their
             previous treatment has to be changed for this reason breach inclusion criteria and /
             or attachment to one of the study groups.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>María del Mar Benjumea</last_name>
    <phone>955 040 460</phone>
    <email>maria.benjumea@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Torrecardenas</name>
      <address>
        <city>Almería</city>
        <state>Almeria</state>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Serrano</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>October 8, 2015</last_update_submitted>
  <last_update_submitted_qc>October 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

